Drug profile

The FDA adverse-event record for Carafate

35 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Carafate. Species, reactions, and outcomes follow.

#1332 of 2,679
by report volume (all drugs)
35
adverse-event reports
11.4%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Carafate ranks #1331 of 2679 by total reports (35). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1331
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Carafate has 35 reports now versus 34 in that prior snapshot: 1 more (2.9%).

Report change
+1
Death-coded reports
+0
Death-coded share
−0.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Carafate changes

Signature read: death-coded share at 11.4% is the most distinctive stamp on Carafate's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
35
Total Reports
4
Deaths Reported
11.4%
Death-coded share of reports

Active Ingredients

Carafate

Administration Routes

OralUnknown

Species Affected

Dog 31
Cat 4

Most Affected Breeds

Retriever - Labrador 5
Crossbred Canine/dog 4
Chihuahua 2
Boxer (German Boxer) 2
Terrier - Yorkshire 2
Collie - Border 2
Chow Chow 2
Domestic Mediumhair 2
Spaniel - Cocker American 1
Domestic Shorthair 1

Most Reported Reactions

Not eating 8
Lethargy (see also Central nervous system depression in Neurological) 8
Lethargy (see also Central nervous system depression in 'Neurological') 6
Neutrophilia 6
Anorexia 6
Weight loss 6
Leucocytosis NOS 5
Lack of efficacy - NOS 5
Ataxia 5
Diarrhoea 5
Emesis (multiple) 5
Vomiting 4

Outcome Breakdown

Ongoing
19 (54.3%)
Recovered/Normal
7 (20.0%)
Outcome Unknown
4 (11.4%)
Euthanized
3 (8.6%)
Recovered with Sequela
1 (2.9%)
Died
1 (2.9%)

Carafate Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Carafate (#1332 of 2,679 by report volume); death-coded 11.4%. PlainBreed drug row · death-coded share stamp 11.4% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →